SOBI and AstraZeneca in US$2bn+ deal on RS...AstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish … more ➔
Amal bags €21.2m financingSwiss Amal Therapeutics S.A. (Geneva) has raised €21.2m in a series B follow-up financing. more ➔
Antibiotic resistance spreading across Eur...Antimicrobial resistance (AMR) has increased by 32% since 2007 in Europe, according to a brand new report. more ➔
Liquid biopsy: size mattersA new method developed by Swiss, Danish and British researchers allows to detect hard-to-trace tumour-derived DNA in the blood (or ctDNA). more ➔
Themis postpones IPOOne week after Austrian vaccine and cancer immunotherapy specialist Bioscience announced the terms of its initial public offering (IPO) and listing on Euronext Amsterdam, the company has postponed its … more ➔
New checkpoint inhibitor on the blockResearchers at Austrian IMBA have identified a well-known co-factor of amino acid synthesis and monoamine neurotransmitter synthesis to play a prominent role in the development of autoimmunity and … more ➔
BIO-Europe: advanced therapies in focusGene and cell therapies, pediatric drugs, and formulation were just some hot topics discussed in a record number of B2B meetings at BIO-Europe in Copenhagen. more ➔
Dry AMD: Oxurion licences heparanase block...Oxurion NV and Beta Therapeutics Inc have inked an R&D agreement aimed to develop new heparanase inhibitors to treat dry AMD. more ➔
Nanobots heading to eye deliveryGerman researchers have developed a drug delivery nanobot that can propel through the eye. more ➔
Argenx antibody kills AMLArgenx SE announced it achieved an overall response rate of 92% in patients with AML with its anti-TNFSF7 (CD70) antibody cusatuzumab. more ➔
